These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21295981)

  • 1. Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies.
    Lo HP; Bertini E; Mirabella M; Domazetovska A; Dale RC; Petrini S; D'Amico A; Valente EM; Barresi R; Roberts M; Tozzi G; Tasca G; Cooper ST; Straub V; North KN
    Neuromuscul Disord; 2011 Mar; 21(3):194-203. PubMed ID: 21295981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two.
    Schoser B; Jacob S; Hilton-Jones D; Müller-Felber W; Kubisch C; Claus D; Goebel HH; Vita G; Vincent A; Toscano A; Van den Bergh P
    Neuromuscul Disord; 2009 Mar; 19(3):223-8. PubMed ID: 19208478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired rippling muscle disease associated with mild myasthenia gravis: a case report.
    van Schaik SM; Kwa VI; van der Kooi AJ
    J Neurol; 2009 Jul; 256(7):1187-8. PubMed ID: 19277764
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel missense mutation in the caveolin-3 gene in rippling muscle disease.
    Lorenzoni PJ; Scola RH; Vieira N; Vainzof M; Carsten AL; Werneck LC
    Muscle Nerve; 2007 Aug; 36(2):258-60. PubMed ID: 17405141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-mediated rippling muscle disease and myasthenia gravis.
    Bettini M; Gonorazky H; Chaves M; Fulgenzi E; Figueredo A; Christiansen S; Cristiano E; Bertini ES; Rugiero M
    J Neuroimmunol; 2016 Oct; 299():59-61. PubMed ID: 27725122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rippling muscles and myasthenia gravis with rippling muscles.
    Ansevin CF; Agamanolis DP
    Arch Neurol; 1996 Feb; 53(2):197-9. PubMed ID: 8639072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caveolin-3 is aberrantly expressed in skeletal muscle cells in myasthenia gravis.
    Iwasa K; Furukawa Y; Yoshikawa H; Yamada M
    J Neuroimmunol; 2016 Dec; 301():30-34. PubMed ID: 27863830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrically active immune-mediated rippling muscle disease preceding breast cancer.
    Liewluck T; Goodman BP; Milone M
    Neurologist; 2012 May; 18(3):155-8. PubMed ID: 22549359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of autoantibodies associated with rippling muscles and myasthenia gravis that recognize skeletal muscle proteins: possible relationship of antigens and stretch-activated ion channels.
    Walker GR; Watkins T; Ansevin CF
    Biochem Biophys Res Commun; 1999 Oct; 264(2):430-5. PubMed ID: 10529381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired rippling muscle disease with myasthenia gravis.
    Greenberg SA
    Muscle Nerve; 2004 Jan; 29(1):143-6. PubMed ID: 14694511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunopathology of myasthenia gravis.
    Lennon VA
    Hum Pathol; 1978 Sep; 9(5):541-51. PubMed ID: 309428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-mediated rippling muscle disease: another inflammatory myopathy in myasthenia gravis.
    Liewluck T
    Arch Neurol; 2010 Jul; 67(7):896-7; author reply 897. PubMed ID: 20625103
    [No Abstract]   [Full Text] [Related]  

  • 14. Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies.
    Rigamonti A; Lauria G; Piamarta F; Fiumani A; Agostoni E
    J Neurol Sci; 2011 Mar; 302(1-2):112-3. PubMed ID: 21236448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new missense mutation in caveolin-3 gene causes rippling muscle disease.
    Dotti MT; Malandrini A; Gambelli S; Salvadori C; De Stefano N; Federico A
    J Neurol Sci; 2006 Apr; 243(1-2):61-4. PubMed ID: 16458928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma.
    Mygland A; Tysnes OB; Matre R; Volpe P; Aarli JA; Gilhus NE
    Ann Neurol; 1992 Oct; 32(4):589-91. PubMed ID: 1333745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult onset acquired myasthenia gravis in three Great Dane littermates.
    Kent M; Glass EN; Acierno M; Shelton GD
    J Small Anim Pract; 2008 Dec; 49(12):647-50. PubMed ID: 18684140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rippling muscle disease: variable phenotype in a family with five afflicted members.
    Jacobi C; Ruscheweyh R; Vorgerd M; Weber MA; Storch-Hagenlocher B; Meinck HM
    Muscle Nerve; 2010 Jan; 41(1):128-32. PubMed ID: 19697367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
    Romi F; Skeie GO; Aarli JA; Gilhus NE
    Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis.
    Müller-Felber W; Ansevin CF; Ricker K; Müller-Jenssen A; Töpfer M; Goebel HH; Pongratz DE
    Neuromuscul Disord; 1999 Dec; 9(8):604-7. PubMed ID: 10619721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.